FDA approves 'potential blockbuster' migraine jab from Lundb...

The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class.

Amgen, Allergan join Rituxan biosimilar challenge with FDA f...

UCB/Amgen's Evenity approved in Europe after appeal

UCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a regulatory rejection, to become the first new drug for the condition s

Amgen strikes outcomes-based payment plan for Enbrel with Ab...

Pharmacy benefit manager Abarca has announced a US reimbursement contract with Amgen for its Enbrel (etanercept) inflammatory diseases drug that will see rebates issued should patients stop

FDA finally approves Sandoz's Neulasta biosimilar, but will ...

The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell booster Neulasta.

Amgen pays $2.7bn to harness BeiGene’s China marketing muscl...